What is the SPRINTER Study?
The SPRINTER Study is a Phase 3 clinical study; this means that researchers are testing the investigational drug in a large number of people with the target disease/condition. Before a drug can be evaluated in a Phase 3 clinical study, it will have been tested in a smaller group of people to assess both its safety and potential effectiveness in the patient population being investigated.
The aim of the SPRINTER Study is to assess the safety and effectiveness (how well something works) of an investigational drug called #SNG001 in men and women hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, also known as coronavirus disease 2019 (#COVID-19).
The trial is a randomised, placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients.
The local Principal Investigator is Professor Dominick Shaw of the NIHR Nottingham Biomedical Research Centre
This study is now fully completed